New hope for rare blood cancer: zanubrutinib trial targets untreated patients

NCT ID NCT07169331

Ongoing Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth, and the study will measure tumor shrinkage and response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (Brukinsa)
What this could lead to: If successful, this study could confirm zanubrutinib as a safe and effective first treatment for Chinese patients with Waldenström macroglobulinemia, helping control the disease.
What could go wrong: This is a small, single-arm study with only 18 participants, so results may not apply broadly. As a phase 4 trial, the drug is already approved, but side effects or lack of strong response are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTRÖM'S MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTRÖM'S MACROGLOBULINEMIA

Contacts and locations

Locations

Affiliated Hospital of Hebei University

Baoding, Hebei, 071000, China
Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
Xiangya Hospital of Central South University

Changsha, Hunan, 410008, China
Yichang Central Peoples Hospital

Yichang, Hubei, 443003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.